🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› C3 Glomerulopathy
Clinical trial register · United Kingdom · industry-sponsored

C3 Glomerulopathy Trials in the UK

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2852 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 17 Sep 2026, 08:23 UTC
2852
Studies in scope
industry-sponsored, all four open statuses
1378
Recruiting now
open to new participants
540
Lead sponsors
across recruiting studies
Top sites
Newcastle upon Tyne 2 London 2 Cardiff 1 Manchester 1 Nottingham 1
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Novartis Pharmaceuticals1 Apellis Pharmaceuticals, Inc.1 Omeros Corporation1
Site city
Newcastle upon Tyne2 London2 Cardiff1 Manchester1 Nottingham1
All 6 cities
Target enrolment
to
3 of 2852 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN
NCT06209736C3 Glomerulopathy, Idiopathic Immune Complex-Mediated Glomerulonephritis
Omeros Corporation
Phase 2
20
Leicester, Newcastle upon Tyne
2024-03-01
Active, closed
An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
NCT05809531C3G, IC-MPGN, C3 Glomerulopathy, C3 Glomerulonephritis
Apellis Pharmaceuticals, Inc.
Phase 3
100
London, Manchester, Nottingham
2023-05-29
Recruiting
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
NCT03955445C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis
Novartis Pharmaceuticals
Phase 3
225
Newcastle upon Tyne, Cardiff, London
2019-10-03
Rows per page Showing 1–3 of 3
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 18 September 2026. https://priyalifescience.com/clinical-trials-uk/condition/c3-glomerulopathy

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.